3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
7
Sarcoma
2
Breast
2
Plasma cell
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
33
Lenalidomide
14
pomalidomide
12
daratumumab
12
Bortezomib
12
venetoclax
7
Cyclophosphamide
7
isatuximab
6
Therapeutics
6
trametinib
4
carfilzomib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
fludarabine
3
dabrafenib
3
Vemurafenib
3
Rituximab
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Drug Therapy
3
Denosumab
3
Ciprofloxacin
3
Calcium Dobesilate
3
ridaforolimus
2
pembrolizumab
2
molibresib
2
liposomal amphotericin B
2
fludarabine phosphate
2
cobimetinib
2
afuresertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
talazoparib
×
Plasma cell
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled